Literature DB >> 21376723

Estrogen receptor ligands counteract cognitive deficits caused by androgen deprivation in male rats.

Natalia Lagunas1, Isabel Calmarza-Font, Daniela Grassi, Luis M Garcia-Segura.   

Abstract

Androgen deprivation causes impairment of cognitive tasks in rodents and humans, and this deficit can be reverted by androgen replacement therapy. Part of the effects of androgens in the male may be mediated by their local metabolism to estradiol or 3-alpha androstanediol within the brain and the consequent activation of estrogen receptors. In this study we have assessed whether the administration of estradiol benzoate, the estrogen receptor β selective agonist diarylpropionitrile or the estrogen receptor α selective agonist propyl pyrazole triol affect performance of androgen-deprived male Wistar rats in the cross-maze test. In addition, we tested the effect of raloxifene and tamoxifen, two selective estrogen receptor modulators used in clinical practice. The behavior of the rats was assessed 2 weeks after orchidectomy or sham surgery. Orchidectomy impaired acquisition in the cross-maze test. Estradiol benzoate and the selective estrogen receptor β agonist significantly improved acquisition in the cross-maze test compared to orchidectomized animals injected with vehicle. Raloxifene and tamoxifen at a dose of 1mg/kg, but not at doses of 0.5 or 2mg/kg, also improved acquisition of orchidectomized animals. Our findings suggest that estrogenic compounds with affinity for estrogen receptor β and selective estrogen receptor modulators, such as raloxifene and tamoxifen, may represent good candidates to promote cognitive performance in androgen-deprived males.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376723     DOI: 10.1016/j.yhbeh.2011.02.014

Source DB:  PubMed          Journal:  Horm Behav        ISSN: 0018-506X            Impact factor:   3.587


  8 in total

1.  Sex differences in the neural substrates of spatial working memory during adolescence are not mediated by endogenous testosterone.

Authors:  Gabriela Alarcón; Anita Cservenka; Damien A Fair; Bonnie J Nagel
Journal:  Brain Res       Date:  2014-10-12       Impact factor: 3.252

2.  Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women.

Authors:  Paul Newhouse; Kimberly Albert; Robert Astur; Julia Johnson; Magdalena Naylor; Julie Dumas
Journal:  Neuropsychopharmacology       Date:  2013-07-19       Impact factor: 7.853

3.  Selective estrogen receptor modulators regulate dendritic spine plasticity in the hippocampus of male rats.

Authors:  Ignacio González-Burgos; Martha C Rivera-Cervantes; Dulce A Velázquez-Zamora; Alfredo Feria-Velasco; Luis Miguel Garcia-Segura
Journal:  Neural Plast       Date:  2011-11-02       Impact factor: 3.599

4.  The effects of tamoxifen on learning, memory and brain tissues oxidative damage in ovariectomized and naïve female rats.

Authors:  Hoda Zabihi; Mahmoud Hosseini; Masoume Pourganji; Shahrbanoo Oryan; Mohammad Soukhtanloo; Saeed Niazmand
Journal:  Adv Biomed Res       Date:  2014-10-21

5.  Hippocampal serotonin-2A receptor-immunoreactive neurons density increases after testosterone therapy in the gonadectomized male mice.

Authors:  Emsehgol Nikmahzar; Mehrdad Jahanshahi; Amir Ghaemi; Gholam Reza Naseri; Ali Reza Moharreri; Ahmad Ali Lotfinia
Journal:  Anat Cell Biol       Date:  2016-12-31

Review 6.  Cognitive Impacts of Estrogen Treatment in Androgen-Deprived Males: What Needs to be Resolved.

Authors:  Erik Wibowo
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Raloxifene as Treatment for Various Types of Brain Injuries and Neurodegenerative Diseases: A Good Start.

Authors:  Leo Veenman
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

8.  Estrogen receptor α functions in the regulation of motivation and spatial cognition in young male rats.

Authors:  Katrin Meyer; Volker Korz
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.